Market News & Trends
Galena Biopharma Enters Merger Agreement With SELLAS Life Sciences
Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd recently announced they have entered into an all stock definitive merger agreement under which SELLAS will…
Humanigen Announces Completion of Bioavailability Study
Humanigen, Inc. recently announced it has completed enrollment and follow-up of subjects in its human bioavailability study for benznidazole. The bioavailability study is a key…
SGS Expands & Increases Capacity 50%
SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, is expanding its facility in Lincolnshire, in the northern suburbs of Chicago, IL. The expansion…
Avista Pharma Solutions Completes Expansion of Analytical Laboratories
Avista Pharma Solutions, Inc. recently announced that the expansion and upgrades to the Analytical Laboratories at its Durham, NC, facility are now complete. These enhancements…
Cambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity
Cambrex Corporation recently announced it is to invest $24 million in a new facility to manufacture highly potent APIs (HPAPIs) at its Charles City, IA,…
Aclaris Therapeutics Acquires Confluence Life Sciences
Aclaris Therapeutics Acquires Confluence Life Sciences Aclaris Therapeutics, Inc. recently announced it has acquired Confluence Life Sciences, Inc., a privately held biotechnology company focused on…
WuXi AppTec Immunotherapy Report: Biotech Sector Will Drive Biggest Advancements in Decades on Cancer Treatments
Small nimble biotechs to introduce a “golden age” of next-generation therapies like CAR-T, combination therapies, innate immune system approaches, and newer check-point inhibitors …
WuXi’s Pharmaceutical Development Services Division Merges With STA
STA Pharmaceutical Co., Ltd. – a WuXi AppTec group company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing…
US Oncology Research & Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations
Epizyme, Inc. and US Oncology Research recently announced a collaboration to screen and identify relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma…
CrownBio Launches Innovative Inflammatory Disease Models to Advance Preclinical Research
Crown Bioscience recently announced the launch of preclinical models of inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) to help inform decision-making in preclinical drug…
CordenPharma to Invest Millions Into New Manufacturing Line for Veterinary Drug Products
CordenPharma Plankstadt recently announced the design and installment of a new manufacturing line dedicated to producing Veterinary Drug Products for 500-kg scale batch sizes to…
Bellerophon Announces FDA Agreement on Phase 2b Study Design
Bellerophon Therapeutics, Inc. recently announced agreement with the US FDA on the Phase 2 study design for INOpulse in pulmonary hypertension associated with Interstitial Lung…
Biological Bypass Shows Promise in Coronary Artery Disease
A new gene therapy that targets the heart and requires only one treatment session has been found safe for patients with coronary artery disease, according…
DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients
DBV Technologies recently announced that the first patient has been enrolled in EPITOPE (EPIT in TOddlers with PEanut Allergy), a global, Phase III clinical trial…
UPM Pharmaceuticals Successfully Serializes Its First Pharmaceutical Product
UPM Pharmaceuticals successfully serialized their first product in May of this year. UPM anticipates having all of their clients' products serialized by November 2017. In…
Inotek Announces Top-Line Results of Phase II Fixed-Dose Combination Trial, Explores Strategic Alternatives
Inotek Pharmaceuticals Corporation recently announced top-line results of the Phase 2 fixed-dose combination (FDC) trial of trabodenoson and latanoprost for the treatment of glaucoma. The…
Nektar Therapeutcs Presents New Preclinical Data for First-In-Class Regulatory T Cell Stimulator
Nektar Therapeutics recently announced positive preclinical results for NKTR-358, a first-in-class resolution therapeutic for autoimmune disease. The new preclinical data demonstrate that treatment with NKTR-358…
Oncology Venture & Eisai Forge Exclusive Global License Agreement
Oncology Venture AB and 2X Oncology, Inc. recently announced that Oncology Venture has entered into an exclusive global license agreement with Eisai Inc. for Eisai’s…
Pfizer Partners With Catalent for Exclusive Long-Term Supply Agreement
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, recently announced that…
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Daiichi Sankyo Co., Limited (hereafter, Daiichi Sankyo), Max Planck Innovation GmbH and the Lead Discovery Center GmbH have signed an agreement providing Daiichi Sankyo with…
